Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E3 ubiquitin-protein ligase TRIM36 is a cytoskeletal-associated enzyme of the tripartite motif (TRIM) family, characterized by a RING finger, B-box type 1 and 2, and coiled-coil domains, with prominent roles in ubiquitinating target proteins and regulating their degradation via the proteasome[1][2][3]. TRIM36 is notably involved in cell cycle regulation, chromosome segregation, and organization of the microtubule cytoskeleton, as well as being essential for embryonic dorso–ventral axis formation and neural tube closure in early development[1]. It is also highly expressed in testis, participating in the acrosome reaction during spermatogenesis[1]. Loss-of-function mutations result in neural tube defects such as anencephaly, and disruptions in its activity are linked to cellular proliferation and apoptotic changes, hinting at possible tumor suppressor or oncogenic functions depending on context[1][2][3]. There are no known drugs directly targeting TRIM36 as of current knowledge.
For hypothetical drugs: Inhibition or modulation of E3 ligase activity (would affect substrate ubiquitination and degradation)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E3 ubiquitin-protein ligase TRIM36 (TRIM36).